Core Viewpoint - Bruker Corporation reported disappointing second-quarter financial results, missing both earnings and sales expectations, and subsequently lowered its FY2025 guidance [1][2][3] Financial Performance - Quarterly earnings were reported at 32 cents per share, below the analyst consensus estimate of 44 cents per share [1] - Quarterly sales amounted to $797.40 million, missing the analyst consensus estimate of $810.43 million [1] Guidance Revision - FY2025 adjusted EPS guidance was cut from a range of $2.40-$2.48 to $1.95-$2.05 [2] - FY2025 sales guidance was lowered from $3.480 billion-$3.550 billion to $3.430 billion-$3.500 billion [2] Market Conditions - Demand for life-science research instruments is currently under pressure, particularly in the US academic market, biopharma, and industrial markets [3] - Factors such as tariffs and currency headwinds have impacted performance, which could not be offset by price and cost actions [3] Analyst Reactions - Stifel analyst Daniel Arias maintained a Hold rating and reduced the price target from $48 to $40 [6] - Wells Fargo analyst Brandon Couillard maintained an Overweight rating and lowered the price target from $60 to $50 [6]